BLRX
BioLineRx Ltd.·Healthcare
2.29
0.439%(+0.01)
Market ClosedLast Updated: — ET
52W L: $2.1552W H: $7.77
BLRX NEWS
businesswire.com
3d ago
Hemispherian Initiates Phase 1/2a Clinical Trial of GLIX1 in Glioblastoma
OSLO, Norway--(BUSINESS WIRE)--Hemispherian AS, a clinical-stage oncology company developing novel small molecule therapeutics, today announced the initiation of a first-in-human Phase 1/2a clinical trial of GLIX1 in patients with recurrent and progressive glioblastoma (GBM) and other high-grade gliomas (NCT07464925). The study is being conducted in collaboration with BioLineRx Ltd. (NASDAQ/TASE: BLRX).
prnewswire.com
Mar 26
BioLineRx Announces Initiation of Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)
GLIX1, a TET2 activator , is a first -in- class , oral, small molecule targeting DNA damage response in glioblastoma and other cancers GLIX1 has demonstrated potent anti-tumor activity in multiple GBM models, excellent blood-brain barrier penetration and a favorable safety profile in preclinical toxicology studies Study is being conducted by world-leading glioblastoma investigators, led by Dr. Roger Stupp TEL AVIV, Israel, March 26, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced the initiation of a first-in-human, Phase 1/2a study of GLIX1 for the treatment of recurrent and progressive GBM and other high-grade glioma (NCT07464925).
seekingalpha.com
Mar 23
BioLineRx Ltd. (BLRX) Q4 2025 Earnings Call Transcript
BioLineRx Ltd. (BLRX) Q4 2025 Earnings Call Transcript
prnewswire.com
Mar 23
BioLineRx Reports 2025 Financial Results and Provides Corporate Update
- On track to initiate Phase 1/2a clinical trial of GLIX1 for treatment of glioblastoma (GBM) by end of this month - - GLIX1 is positioned to potentially address unmet needs for novel and more effective cancer treatments by targeting DNA damage response mechanisms - - Management to host conference call today, March 23, at 8:30 am EDT - TEL AVIV, Israel, March 23, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today reported its audited financial results for the year ended December 31, 2025, and provided a corporate update.
defenseworld.net
Mar 21
BioLineRx (BLRX) Projected to Post Quarterly Earnings on Monday
BioLineRx (NASDAQ: BLRX - Get Free Report) is expected to release its Q4 2025 results before the market opens on Monday, March 23rd. Analysts expect the company to announce earnings of ($0.50) per share and revenue of $0.4920 million for the quarter. Interested persons may visit the the company's upcoming Q4 2025 earning results page for
feeds.benzinga.com
Mar 20
Top Wall Street Forecasters Revamp BioLineRx Expectations Ahead Of Q4 Earnings
BioLineRx Ltd. (NASDAQ: BLRX) to release Q4 earnings on March 23. Previous Q3 losses were 22 cents per share, with sales of $427,000. Analysts rate the stock favorably.
